Imris today reported that it saw sales grow 44% last year and has seen sales rise 68% this year after it was reorganized in a bankruptcy purchase 2 years ago.
The Minnetonka, Minn.-based company said that in the past 2 years, it has inked multi-million dollar contracts with hospitals across the globe and has added and plans to continue adding new employees to support business and company growth.
“We’re proud of the progress we’ve made in a short period of time which includes active investments in future growth opportunities that leverage our talent and expertise in consulting, designing, creating and supporting Imris Surgical Theatres. We’re focused on building the most advanced intraoperative surgical theatres with optimized workflow for neurosurgeons, better outcomes for patients and maximum value for hospitals,” prez & CEO Andrew Flanagan said in a prepared statement.
The company produces the Imris Surgical Theater solution, which features celing-mounted, moving intraoperative magnetic resonance imaging or computed tomgoraphy imagers, which the company claims is the world’s only such platform.
In 2015, former Siemens Healthcare (NYSE:SI) North America division chief Dr. Gregory Sorensen took out a minority stake in Deerfield Imaging, the former Imris business the investment company bought out of bankruptcy.
Imris and 2 subsidiaries, including its NeuroArm Surgical business, filed for Chapter 11 bankruptcy protection in 2014, under a bailout plan with Deerfield Management.